Consumer goods and personal care giant Kimberley-Clark is set to acquire Tylenol-maker Kenvue in a monumental $40 billion deal involving both stock and cash, marking a significant merger within the consumer health goods sector. This landmark transaction will position Kimberley-Clark to surpass Unilever, becoming the second-largest company in health and wellness products, trailing only Procter & Gamble Co. The timing of this acquisition is particularly notable as Kenvue’s flagship drug, Tylenol, faces scrutiny from the White House and struggles with fluctuating demand.

Details of the intricate $40 billion deal reveal that Kenvue shareholders are slated to receive $3.50 per share in cash, alongside 0.14625 Kimberly-Clark shares for each Kenvue share they hold. This package aggregates to a total deal value of $21.01 per share, implying an impressive equity value of $40.32 billion, according to Reuters calculations. The offer represents a substantial 46.2% premium over Kenvue stock's last closing price. Furthermore, the companies have stated that the deal holds an enterprise value of approximately $48.7 billion. Upon the closure of the merger, current Kimberley-Clark shareholders are expected to own about 54% of the combined entity, with Kenvue shareholders holding the remaining 46%.

The strategic impetus behind Kimberley-Clark's move is a significant transformation aimed at pivoting its portfolio towards higher-growth and higher-margin businesses. Mike Hsu, the current CEO of Kimberly-Clark, will retain his position as chief executive of the merged company, emphasizing that Kenvue’s collection of brands perfectly aligns with this strategic direction. Kimberly-Clark anticipates generating approximately $2.1 billion in annual cost savings as a direct result of this acquisition.

The announcement triggered diverse reactions in the stock market; shares of Kimberly-Clark, known for brands like Kleenex and Huggies, experienced a 16% decline in premarket trading. Conversely, Kenvue's shares saw a significant surge, climbing 19%. While media reports had circulated since June regarding a potential acquisition, the formal announcement of the Kenvue-Kimberley Clark deal came earlier than many had expected.

The acquisition arrives at a challenging period for Kenvue, which has been grappling with diminishing demand for its products. A major factor contributing to this struggle is the intense White House scrutiny facing Tylenol, stemming from allegations that the drug may cause autism and ADHD in children if consumed by mothers during pregnancy. Although US Health and Human Services Secretary Robert F. Kennedy Jr. acknowledged a lack of definitive evidence proving Tylenol causes autism, he reiterated his view that there were “very suggestive” signs of a link.

Beyond the Tylenol controversy, Kenvue's investor sentiment has been dampened by ongoing lawsuits alleging that its baby powder products caused cancer. The company has also had a rather turbulent and short run as an independent entity since its split from Johnson & Johnson two years prior, struggling to find solid footing. The deal is projected to officially close in the second half of 2026.